Page 126 - CombinedTest_Neat

Site Performance Summary:
Willard Supply Expense is over $123K, or 50%. Key drivers include Drugs,
$67K over budget, Lab, $28K over budget, and Non-CRM Implants, $27K
over budget.

Total Admissions up 7% compared to budget, 16% over PY. Additionally,
Total Patient Days 16% over budget. Inpatient Surgeries matched budget,
while Outpatient Surgeries were 4% below budget. Net Revenue 21% over
budget.

Key Challenges: 2-3 key contributors for each expense subaccount
Under budget even with admissions and total patient days both over budget.

Willard Leader's Summary
Med/Surg

Oncology is at max volume. Patients even being sent to Tiffin for treatment.

3 Key Cardinal orders totaling $70K:
Krystexxa, treats gout, O/P Injection, $37K
Rx Keytruda, chemo treatment, O/P Injection, $18.3K
TNKase, reordered to replenish stock, $14.9K

Ortho trending higher volumes in Dec. visible from YOY, spend was equal
to PY.
Implant Other subaccount saw significant spend from an increase in bunions
and hammertoe corrections for December by Dr. Bohach.
Implants
One patient had non-healing wound that required (2) 44CM Apligrafs
totaling $2.6K.
Ordering issue left two implant trays empty; had to restock, $4.3K

Bulk purchase of 6-12 month supply of Liquichek diabetes, hemoglobin,
and immunoassay control prodcuts - $20K; necessary to buy in bulk for lot
control

Lab

Actions Taken/Planned:
Volume Data
Alt Sourcing
Capital Avoidance